Assessing the Annual Risk of Recurrence Following Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Diffuse Malignant Peritoneal Mesothelioma Patients.

Date publication

septembre 2025

Journal

Annals of surgical oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BRIGAND Cécile

Tous les auteurs :
Péron J, Essadi I, Rousset P, Villeneuve L, Benzerdjeb N, Goéré D, Sourrouille I, Sgarbura O, Ferron G, Pocard M, Dumont F, Bereder JM, Brigand C, Glehen O, Kepenekian V,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41006791

Résumé

Selected diffuse malignant peritoneal mesothelioma (DMPM) patients may be radically treated with complete cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Two thirds of them recur with the possibility of iterative CRS-HIPEC and/or systemic chemotherapy. The postoperative follow-up management is based on scarce data. The recurrence profile was explored in a large national database to challenge the standard follow-up protocol.

Mots clés

CRS, DMPM, Follow-up, HIPEC, Peritoneal mesothelioma

Référence

Ann Surg Oncol. 2025 09 26;: